- Conditions
- COPD
- Interventions
- Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COPD
- Interventions
- Glycopyrronium and Formoterol Fumarate (GFF) Dose 1, Glycopyrronium and Formoterol Fumarate (GFF) Dose 2, Glycopyrronium (GP) Dose 1, Glycopyrronium (GP) Dose 2
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- Inhaled BGF (PT010) Dose 1, Inhaled BGF (PT010) Dose 2, Inhaled BGF (PT010) Dose 3, Inhaled GFF (PT003), Inhaled Symbicort Dose 1, Inhaled Symbicort Dose 2
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 1,756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 44
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 2,103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 121
- States / cities
- Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more